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Abstract
Endoplasmic reticulum (ER) stress represents an early pathological event in amyotrophic lateral sclerosis (ALS). ATF4 is a key
ER stress transcription factor that plays a role in both adaptation to stress and the activation of apoptosis. Here we
investigated the contribution of ATF4 to ALS. ATF4 deficiency reduced the rate of birth of SOD1G86R transgenic mice. The
fraction of ATF42/2-SOD1G85R transgenic mice that were born are more resistant to develop ALS, leading to delayed disease
onset and prolonged life span. ATF4 deficiency completely attenuated the induction of pro-apoptotic genes, including BIM
and CHOP, and also led to quantitative changes in the ER protein homeostasis network. Unexpectedly, ATF4 deficiency
enhanced mutant SOD1 aggregation at the end stage of the disease. Studies in the motoneuron cell line NSC34
demonstrated that knocking down ATF4 enhances mutant SOD1 aggregation possibly due to alteration in the redox status
of the cell. Our results support a functional role of ATF4 in ALS, offering a novel target for disease intervention.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive and deadly
adult-onset motoneuron disease characterized by muscle weak-
ness, spasticity, atrophy, paralysis and premature death. The
pathological hallmark of ALS is the selective degeneration of
motoneurons in the spinal ventral horn, most brainstem nuclei and
cerebral cortex [1,2]. The majority of ALS patients lacks a defined
genetic component, and is considered sporadic, while approxi-
mately 10% of cases are familial (fALS) [1]. Many disease-
causative genes have been identified; including hexanucleotide-
repeat expansion in the intronic region of C9orf72, superoxide
dismutase-1 (SOD1), TARDBP, FUS, and many others [1].
Overexpression of fALS-linked SOD1 mutants in transgenic mice
recapitulates essential features of the human pathology, provoking
age-dependent protein aggregation, paralysis, motoneuron degen-
eration and muscle atrophy [2,3]. The primary mechanisms
contributing to the progressive motoneuron loss in ALS remains
controversial, and multiple perturbations of cellular function/
processes have been uncovered in ALS-affected motoneuron and
glial cells [3]. Accumulating evidence highlights a functional
involvement of endoplasmic reticulum (ER) stress in both sALS
and fALS pathogenesis, representing an early event in the
pathology [4,5,6].
ER stress is triggered by a number of conditions that interfere with
the oxidative-protein folding process at the ER lumen, leading to
accumulation of abnormally folded proteins [7]. ER stress engages
the unfolded protein response (UPR), an integrated signal
transduction pathway that increases the protein folding capacity
and quality control mechanisms of the ER, mitigating the load of
unfolded proteins [8]. Conversely, chronic ER stress results in
apoptosis of irreversibly damaged cells through diverse comple-
mentary mechanisms [9]. The UPR is activated by threemain stress
sensors, including PKR-like ER kinase (PERK), Inositol-requiring
transmembrane kinase/endonuclease (IRE1), and activating tran-
scription factor 6 (ATF6). Upon activation PERK reduces protein
translation into the ER by phosphorylating the eukaryotic initiation
factor 2 alpha (eIF2a), which contributes to attenuate the misfolded
protein overload [10]. In addition, phosphorylation of eIF2a allows
the expression of activating transcription factor 4 (ATF4), a key
factor that upregulates UPR genes that function in amino acid and
redox metabolism, autophagy, protein folding, and apoptosis
[7,11,12,13]. PERK has dual signaling outputs toward promoting
cell survival or the induction of cell death by integrating information
about the intensity and kinetic of exposure to ER stress. In the
control of apoptosis, ATF4 drives the expression of the transcription
factor GADD153/CHOP, modulating the levels of multiple pro-
apoptotic components including BIM and PUMA (see examples in
[14,15,16]), and could also induce BIM expression through the
microRNApathway aswe recently described [17]. Sustained PERK
signaling also contributes to apoptosis by enhancing oxidative stress
and by resuming protein synthesis after prolonged ER stress
[18,19,20]. Although PERK deficiency enhances the susceptibility
of cells to apoptosis in mouse embryonic fibroblasts [11], its
expression in neurons has been shown to operate as a central
regulator of oxidative stress genes affecting cell survival during
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hypoxia [21]. In contrast, another study suggested thatCHOP could
also have a neuroprotective activity against hypoxia [22]. PERK/
ATF4 also enhances the expression of the anti-apoptotic protein
GRINA, modulating ER calcium homeostasis [23]. In addition to
ER stress, the eIF2a/ATF4 pathway can be engaged by other
stimuli involving kinases stimulated by viral infections, metabolic
alterations, among other factors, suggesting a broad function of the
eIF2a/ATF4 pathway as a stress integrator. IRE1 controls the
expression of the transcriptional factor X-Box-binding protein 1
(XBP1) through an unconventional splicing process, whereas
processing of ATF6 at the Golgi releases the cytosolic domain that
acts as a transcription factor [8]. Both XBP1 and ATF6 control a
subset of UPR-target genes related to protein folding and quality
control mechanisms. Overall, UPR signaling responses modulate
the expression of a large spectrum of partially overlapping target
genes to recover ER homeostasis or to trigger cell death programs
depending on the nature of the stress stimuli [9].
Different groups have reported the activation of the UPR in
human post-mortem samples derived from ALS patients [24,25],
including XBP1 and ATF4 expression as we reported [26]. The
occurrence of ER stress has been also recapitulated in most
cellular and animal models of fALS (reviewed in [4,5]).
Remarkably, a systematic gene-expression profile study in mutant
SOD1 transgenic mice indicates that only affected motoneurons
are selectively prone to undergo chronic ER stress, occurring
before the earliest denervation in asymptomatic animals [27]. The
possible effects of decreasing ER stress levels in ALS were tested
using pharmacological approaches. Treatment of mutant SOD1
mice with salubrinal, a small molecule that selectively induces
eIF2a phosphorylation, significantly protected against disease
progression in a small cohort of animals [27]. Consistent with this
report, perk haplo-insufficiency (PERK+/2 mice) exacerbated the
severity of experimental ALS, associated with enhanced neuronal
loss and mutant SOD1 aggregation [28]. Surprisingly, the loss of
one perk allele was not sufficient to attenuate the induction of
ATF4 in early symptomatic mice, reflected in unaltered induction
of CHOP and BiP in Perk+/2-mutant SOD1 mice [28]. Thus, the
protective effects of targeting PERK in this study are possibly
attributed to a mild inhibition of protein translation. In contrast,
we showed that XBP1 deficiency protects against the development
of ALS [26]. Similarly, targeting ASK1, a downstream signaling
component of IRE1 [29], or ablating the expression of BIM or
PUMA delays ALS [30,31]. These studies illustrate the complex
nature of the UPR, where the functional impact of the pathway to
ALS may actually depend on the specific outputs regulated by
particular UPR signaling modules [9]. Here we investigated the
specific contribution of ATF4 to ALS pathogenesis. Our results
uncovered a complex scenario where ATF4 deficient animals were
significantly resistant to develop ALS pathology. The protective
effects of ATF4 deficiency were related to the down-regulation of
the pro-apoptotic factors including CHOP and BIM, and altered
expression of key ER foldases. Our results indicate a functional
contribution of ATF4 in ALS pathogenesis.
Materials and Methods
Ethics Statement
The animal care and all animal experiments were performed
according to procedures approved by ‘‘Guide for the Care and
Use of Laboratory Animals’’ (Commission on Life Sciences.
National Research Council. National Academy Press 1996) and
approved by the Bioethical Committee of the Faculty of Medicine,
University of Chile (protocol number CBA0399 FMUCH).
Materials and Plasmids
Tunicamycin (Tm), pepstatin, E64D, and puromycin were
purchased from Sigma (St Louis, MO, USA). Cell media and
antibiotics were obtained from Life Technologies (Maryland,
USA). Fetal calf serum was obtained from Atlanta Biologicals
(Norcross, GO, USA). DAPI was purchased from Molecular
Probes (Eugene, OR, USA). All transfections were performed
using the Effectene reagent (Qiagen, Germantown, MD, USA).
DNA was purified with Qiagen kits.
The human SOD1-EGFP expression vectors (the wild-type and
the G85R mutant) were provided by Dr. Julie Atkin and described
in [32]. In brief, primers were designed to introduce a SalI site to
allow subcloning SOD1 mutants into pEGFP-N1 (Clontech, Palo
Alto, CA) and to remove the SOD1 translation stop codon.
Mutants were generated via site directed mutagenesis of the
SOD1WT template using the Quick Change kit (Stratagene, La
Jolla, CA). The plasmids to express HyPer-ERlum and ERO1La-
mCherry were described before [33]. The HyPer-ERlum consists in
a modified fluorescent protein that acts as a high sensitive H2O2
biosensor developed by Belousov et al. [34]. In the presence of
H2O2, the excitation peak at 420 nm of HyPer-ERlum is reduced
proportionally to the increased in the peak at 500 nm. The
construct was modified by Enyedi et al.making this sensor target to
the lumen of the ER [33] and allows the measure of H2O2 levels at
the ER in living cells. The pcDNA3.1/V5 plasmids to express PDI
and ERp57 were kindly provided by Dr. Neill Bullheid (University
of Glasgow, UK).
Knockdown of UPR components
We generated stable motoneuron cell lines with reduced levels
of ATF4 using methods previously described [26] by targeting
their respective mRNAs with shRNAs using the lentiviral
expression vector pLKO.1 and puromycin selection. As control,
empty vector or shRNA against the luciferase gene were employed.
Constructs were generated by The Broad Institute (Boston, USA),
based on different criteria for shRNA design (see http://www.
broad.mit.edu/genome_bio/trc/rnai.html) [35]. Targeting se-
quence identified for mouse ATF4 was 59-CCGG-GCGAGTG-
TAAGGAGCTAGAAA-CTCGAG-TTTCTAGCTCCTTA-
CACTCGC-TTTTTG-39.
Table 1. Proportion of mice obtained in the generation of
ATF4+/+-SOD1G86R and ATF42/2-SOD1G86R mice.
Number of animals generated:
Non Tg SOD1G86R
Viable
SOD1G86R
(%)
ATF4+/+ 39 36 48
ATF4+/2 231 134 36,7
ATF42/2 15 8 34,7
Total
Animals
463
The percentage of mutant SOD1 transgenic mice obtained in relation to the
equivalent ATF4 genotype of non-transgenic mice is indicated. Total animals
obtained for each genotype is indicated.
doi:10.1371/journal.pone.0066672.t001
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Figure 1. Effects of ATF4 deficiency on disease onset and life span of mutant SOD1 transgenic mice. (A) Body weight was monitored in
SOD1 transgenic mice (SOD1G86R) on an ATF4 wild-type (ATF4+/+) or knockout (ATF42/2) background. Disease onset was defined as the day when
animals lost 5% of total body weight. Bottom panel: The average of disease onset with this parameter was 130 days for ATF4+/+/SOD1G86R (N = 15)
and 183 days for ATF42/2/SOD1G86R (N = 8). (B) In parallel, rotarod performance was monitored in animals presented in B. Disease onset was
determined as the time when animals were not able to perform the task. With this parameter average onset was 147 days for ATF4+/+/SOD1G86R mice
(N= 13) and 209 days for ATF42/2/SOD1G86R (N = 6). Of note, two animals in each group group were excluded on this analysis because they did not
learn the rotarod test. (C) Animal survival was monitored in animals described in A. Life span curves showed an average survival of 137 days for
ATF4+/+/SOD1G86R animals (N = 15) and 155 days for ATF42/2/SOD1G86R (N= 8) mice. In A-C the analysis of control ATF4+/+ (N = 14) and ATF42/2
(N = 4) non-transgenic (Non Tg) groups is also presented. (D) The duration of the disease was calculated by comparing the measurements of
individual animals for life span and disease onset. In all graphs, mean and standard error is presented. p values were calculated with Kaplan-Meier
statistics and indicated in the Figure. n.s.: non significant.
doi:10.1371/journal.pone.0066672.g001
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Assays for mutant SOD1 aggregation and detection of
intracellular inclusions
We developed assays using the transient expression of human
SOD1WT and the mutant and SOD1G85R as EGFP fusion proteins
[26]. These constructs were employed to visualize and quantify the
formation of intracellular SOD1 inclusions in living cells by
fluorescent confocal microscopy. SOD1-containing aggregates
were visualized in total cell extracts prepared in 1% Triton-X-
100 in PBS buffer containing protease inhibitors followed by
sonication and Western blot analysis. For samples treated with
DTT, protein extracts were incubated with 100 mM DTT at
room temperature for 10 min.
Fluorescence measurements
H2O2 levels were assessed using a 406/1.4 NA oil immersion
objective in an IX-81 inverted microscope for fluorescence
Figure 2. Targeting ATF4 alters SOD1 aggregation in mutant SOD1 transgenic mice. Histological characterization of ATF42/2/SOD1G86R
spinal cord. (A) Immunofluorescence analysis of NeuN and Olig2 staining in spinal cord tissue derived from ATF4+/+, ATF4+/+/SOD1G86R and ATF42/2/
SOD1G86R at the late disease stage. Hoechst staining is also presented. A merged image of the three staining is provided together with a zoom of the
selected area. Bar 250 mm. A representative image is presented of the analysis of three independent animals. (B) In the same tissue described in A,
GFAP staining was performed and quantified. A zoom of the selected area is also provided (right panel). The border of the spinal cord tissue is
delineated with a white line Bar 100 mm. (C) SOD1 aggregation was determined in spinal cord protein extracts derived from ATF4+/+(N = 2) ATF4+/+/
SOD1G86R (N = 6) ATF42/2/SOD1G86R (N = 4) and ATF42/2 (N = 3) mice at the symptomatic stage using Western blot analysis. Each well represents an
independent animal. (D) In parallel, brain cortex was analyzed as described in C. Bottom panels of C and D: Mutant SOD1 aggregation was quantified
from experiments presented in C and D, and normalized with the value of HSP90. Average signal of control transgenic mice was normalized to 1.
Mean and standard deviation is presented in all plots. p values were calculated with Student’s t-test, *: p,0.05.
doi:10.1371/journal.pone.0066672.g002
Figure 3. Altered expression of UPR-target genes in mutant SOD1 transgenic mice upon deletion of ATF4. (A) Expression levels of
several ER stress-responsive proteins were monitored in spinal cord extracts derived from ATF4+/+, ATF42/2, ATF4+/+/SOD1G86R and ATF42/2/
SOD1G86R symptomatic mice using Western blot analysis. The image was composed from representative bands cropped from the same gel and film.
(B) Quantification of experiments presented in A. ATF4+/+ (N= 3), ATF42/2 (N = 3), ATF4+/+/SOD1G86R (N = 6) and ATF42/2/SOD1G86R (N = 3). HSP90
was used as loading control, and values were normalized to the average signal obtained in ATF4+/+ mice. (C) In parallel, CHOP and BIM protein levels
were monitored in animals described in A. Mean and standard error is presented. *: p,0.05, calculated with Student’s t-test. n.s.: non significant.
doi:10.1371/journal.pone.0066672.g003
ATF4 Modulates ALS Pathogenesis
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measurements (DSU, Olympus), equipped with a 150-W xenon
lamp (Olympus MT-20). For ratiometric measurement, the
HyPerERlum sensor was excited at 490/420 nm wavelengths
and the fluorescence was filtered at 510 nm was collected and
recorded at 0.2 Hz using a CCD-based imaging system (Olympus
DSU). Coverslips were placed in a chamber and mounted on the
microscope. Cells were incubated in 0.5 ml fresh extracellular
medium containing 145 mM NaCl, 5 mM KCl, 1 mM MgCl2,
2 mM CaCl2, 10 mM HEPES, 10 mM glucose, pH 7.4 kept at
23uC. After acquisition of the baseline measurement, DTT and
H2O2 were added to a final concentration of 10 mM and 1 mM,
respectively, to ensure the functionality of the sensor. The CellR
software (Olympus) software was used for data acquisition. Images
were acquired every 15 s for a period of 300 seconds. The 490/
420 nm fluorescence excitation ratio of HyPer-ERlum was
calculated after background fluorescence subtraction. Mean
fluorescence intensities over individual cells were calculated from
2 min recordings. For time-resolved measurements of fluores-
cence, background subtracted recordings were averaged and
plotted against time. Endogenous peroxides were measured by
incubating control cells and treated with 2.5 mM tunicamycin for
4 h in medium containing 5 mM of 5-(and-6)-chloromethyl-29, 79
dichlorodihydrofluoresceine diacetate (H2DCFDA, Molecular
Invitrogen) at 37uC in a 5% CO2 incubator followed by FACscan
analysis.
Animal Experimentation
Animals were maintained in a quiet, ventilated and temperature
controlled room (23uC) and monitored daily. Mice were housed in
a polystyrene solid bottom plastic cage fitted with a functioning
filter top. Animals were fed with LabDiet pellets and had available
drinking water ad libitum. Animals were maintained with a
standard 12 h light cycle. For animal euthanasia, animals received
intraperitoneal injection of anesthesia (100 mg/kg ketamine plus
10 mg/kg xylazine). ATF4 deficient mice were previously
described [36,37]. ATF4 deficient animals were obtained from
Dr. Laurie Glimcher laboratory (Harvard School of Public Health,
Boston MA, USA) where they were backcrossed to C57BL/6 pure
background. We employed as an ALS model a SOD1G86R
transgenic strain (the equivalent of human SOD1G85R) originally
generated in the FVB/N strain (strain FVB-Tg(Sod1-
G86R)M1Jwg/J, The Jackson Laboratory) [38] in which the
expression of the SOD1 mutant gene is driven by the endogenous
SOD1 promoter. Mutant SOD1 mice were backcrossed to
C57BL/6 for more than six generations. ATF4+/2 mice were
then crossed with ATF4+/2/SOD1G86R transgenic mice to
generate experimental animals. We obtained 8 ATF42/2/
SOD1G86R mice (4 males and 4 females) from 463 animals
obtained (see table 1).
Disease onset analysis
For disease onset determination, we measured three different
parameters over time for each experimental animal: (i) rotarod
performance, (ii) body weight loss and (iii) disease sign scoring. All
this information was analyzed for individual animals to calculate
disease onset for each parameter. We started the collection of
disease-sign data from 5 to 6 weeks after birth for each mouse. For
each parameter a day of onset was defined as follows: We measure
motor performance with the rotarod test for each mouse three
times per week starting at 60 days as described before using an
acceleration protocol measured for total 90 seconds [26]. Disease
onset was defined as the day before the animal was not able to
perform the task. Body weight measurements were performed
three times a week, the same day rotarod was performed, and
onset was defined as the day before the animal loses more than 5%
of the body weight. To determine disease onset by disease sign
observations, we monitored and video recorded the appearance of
abnormal limb-clasping, wobbly gait, the first signs of paralysis in
one hind-limb, ruffling fur, and hunched posture. We assigned to
Figure 4. ATF4 deficiency alters the expression of apoptosis
genes and enhances mutant SOD1 aggregation in NSC34
motoneuron cells. (A) NSC34 cells were stably transduced with
lentiviral vectors expressing shRNA against ATF4 mRNA (shATF4) or
control luciferase mRNA (shLuc). Expression of ATF4 was analyzed after
treatment with 1 mg/mL tunicamycin (Tm) for indicated time. Then,
expression of ATF4, CHOP, PDI and HSP90 levels (loading control) was
monitored by Western blot analysis. The splicing of XBP1 mRNA is
shown by RT-PCR using total cDNA from similar experiments. (B) shLuc
and shATF4 cells were transiently transfected with expression vectors
for SOD1G85R-EGFP. After 72 h, mutant SOD1 aggregation was
monitored by Western blot. Left panel: quantification of SOD1
aggregation levels normalized with HSP90. Mean and standard
deviation is presented from three independent experiments. (C) In
parallel, mutant SOD1 inclusions were visualized by fluorescent
microscopy and quantified (lower panel, bar, 50 mm). A minimum of
150 cells per group was counted. Mean and standard deviation is
presented from three independent experiments.
doi:10.1371/journal.pone.0066672.g004
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each visual observation a score 1 when the symptom appears, 3
when it increases or 5 when the phenotype was severe. For this
parameter disease onset corresponded to the day when the total
score of the animal was more than 10. The end stage of disease
was determined as the time when an animal was not able to right
itself up within 30 seconds after being placed on its back. For
Figure 5. Knocking down ATF4 in NSC34 cells alters the redox state of the ER, contributing to mutant SOD1 aggregation. (A) ROS
levels were determined in shATF4 and shLuc NSC34 cells at basal levels or after treatment with 1 mg/ml Tm for 16 h using dichlorofluorescein (DCF)
staining and FACS analysis. Right panel: Quantification of mean DCF fluorescence. (B) The generation of H2O2 inside the ER was determined in shATF4
and shLuc cells after transient expression of HyPer-ERlum construct. After 72 h, cells were treated or not with 1 mg/ml Tm for 6 h and fluorescence
emission determined by live cell-imaging microscopy. (C) NSC34 shATF4 cells were transiently transfected with SOD1G85R-EGFP plasmid and treated
with 400 mM trolox after 24 h. Two days after mutant SOD1 aggregation was analyzed by Western blot. Left panel: quantification of SOD1
aggregates. (D) NSC34 shATF4 cells were co-transfected with expression vectors for SOD1G85R-EGFP together with ERO1La plasmid or empty vector.
Left panel: Then, mutant SOD1 aggregation was monitored after 72 h by Western blot (left panel, Bar 50 mm). Right panel: In parallel, mutant SOD1
inclusions were visualized by fluorescent microscopy and quantified. (H) Control and shATF4 NSC34 cells were exposed to 5 mg/ml Tm for 16 h and
cell death was detected after propidium iodide (PI) staining, and visualized with a fluorescent microscope. As a positive control, cells were treated for
16 h with 20 mm etoposide (Eto). Data is representative of three independent experiments. Arrows heads shows PI stained cells. Ph C: Phase Contrast.
In all plots, mean and standard deviation is presented of three independent experiments. p value was calculated with Students t-test, *: p,0.05.
doi:10.1371/journal.pone.0066672.g005
ATF4 Modulates ALS Pathogenesis
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disease onset and animal survival measurements we used four
groups of animals: ATF4+/+ non transgenic (7 males and 7
females), ATF4+/+/SOD1G86R (7 males and 8 females), ATF42/
2/SOD1G86R (4 males and 4 females) and ATF42/2 non
transgenic (2 males and 2 females). No differences were observed
by gender analysis (not shown). Of note, two animals of the
ATF4+/+/SOD1G86R and the ATF42/2/SOD1G86R groups (one
male and one female in each group) did not learn the rotation rod
test and were excluded from this specific analysis.
Tissue analysis
To monitor SOD1 pathogenesis in vivo, animals were eutha-
nized and tissue collected for immunohistochemistry and Western
blot analysis at the end stage of the disease. 1.5 cm of lumbar
spinal cord tissue was collected and divided into two fractions used
for Western blot analysis and histology. For immunofluorescence
analysis, tissue was then fixed in 4% paraformaldehyde (PFA) in
0.1 M saline phosphate buffer (PBS) for 48 h followed by standard
procedures for immunofluorescence in tissue. In brief, spinal tissue
was processed on a sucrose gradient (5%, 10% and 30% sucrose in
PBS), cryoprotected with Optimal Cutting Temperature com-
pound (Tissue Tek), and fast frozen using liquid nitrogen. Tissue
was longitudinally sectioned (5 mm thick slices) using a cryostat
microtome (Leica, Nussloch, Germany), as described previously
[39]. Sections were immunostained using the following antibodies:
anti-NeuN 1:300 (MAB377, Millipore Bioscience Research
Reagents), anti-Olig-2 1:200 (ab9610, Millipore Bioscience
Research Reagents), and anti-GFAP 1:1000 (N1506, Dako).
Tissue sections were analyzed with an Olympus IX71 microscope
and images were captured using a QImaging QICAM Fast 1394
camera.
Western blot analysis of motor cortex and spinal cord
protein extracts
After the animal was anesthetized, the brain was removed and
the motor cortex was dissected and immediately frozen for further
analysis. In addition, lumbar spinal cord tissue was collected in the
same animals and homogenized in RIPA buffer (20 mM Tris
pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% DOC, 0.5% triton X-
100) or PBS buffer containing 1% Triton X-100 and a protease
inhibitor cocktail (Roche, Basel, Switzerland). Tissue was sonicat-
ed on ice and then protein concentration was determined by
micro-BCA assay (Pierce, Rockford, IL). The equivalent of 30–
50 mg of total protein was loaded onto SDS-PAGE minigels. The
following antibodies and dilutions were used: anti-Grp78/BiP,
anti-Grp58, anti-PDI, 1:2,000 (Stressgen, San Diego, CA), anti-
XBP-1, 1:2,000 (Biolegend), anti-GFP 1:1000, anti-ATF4 (Santa
Cruz CA), anti-Hsp90 (Santa Cruz, CA), anti-CHOP 1:2,000
(Santa Cruz, CA); anti-SOD1 1:3000 (Calbiochem), anti-V5
1:5000 (Invitrogen), ERO1La 1:2000 (Novus Biologicals) and
LC3 1:3000 (Cell signaling). In general, for Western blotting we
analyzed two ATF4+/+/SOD1WT (1 male, 1 female), six ATF4+/
+/SOD1G86R (3 males and 3 females), and four ATF42/2/
SOD1G86R (2 males and 2 females) followed by protein expression
quantification using image J software.
RNA extraction and RT-PCR
Total mRNA was prepared from spinal cord tissue previously
homogenized in cold PBS followed by Trizol extraction (Invitro-
gen, Carlsbad, CA). cDNA was synthesized with SuperScript III
(Invitrogen, Carlsbad, CA) using random primers p(dN)6 (Roche,
Basel, Switzerland). Quantitative real-time PCR reactions em-
ploying SYBR green fluorescent reagent were performed in an
ABI PRISM 7700 system (Applied Biosystems, Foster City, CA).
The relative amounts of mRNAs were calculated from the values
of comparative threshold cycle by using b-actin as a control.
Primer sequences were designed by Primer Express software
(Applied Biosystems, Foster City, CA) or obtained from the Primer
Bank (http://pga.mgh.harvard.edu/primerbank/index.html). Re-
al time PCR was performed as previously described [26] using the
following primers: bim 59-CGACAGTCTCAGGAGGAACC39
and 59CATTTGCAAACACCCTCCTT39; Chop/gadd153 59-
GTCCCTAGCTTGGCTGACAGA-39 and 59-TGGAGAGC-
GAGGGCTTTG-3 actin 59-TACCACCATGTACCCAGGCA-
39 and 5-9 CTCAGGAGGAGCAATGATCTTGAT-39.
Statistical Analysis
All data are expressed as mean and SEM. Results were
statistically compared using Student’s t-test performed for paired
groups.
Results
Targeting ATF4 on a mutant SOD1 transgenic mouse
model
In order to define the possible contribution of ATF4 to ALS
pathogenesis, we cross-bred ATF4 deficient mice with SOD1G86R
transgenic animals (the equivalent of human SOD1G85R) in a
C57BL/6J genetic background. This ALS model was chosen since
the expression of mutant SOD1 is driven by the endogenous sod1
promoter, and SOD1G86R encodes an enzyme with minimal
SOD1 activity. To generate experimental animals with proper
littermate controls, we then crossed ATF4+/2 with ATF4+/2/
SOD1G86R animals and monitored disease progression. Using this
breeding strategy, we obtained a total of 463 animals. As
predicted, the probability of obtaining a wild-type or a mutant
SOD1 transgenic animal in a wild-type background were almost
identical (Table 1). In sharp contrast, ATF4 haplo-insufficiency
decreased the percentage of SOD1G86R mice generated to 36%
(N=231 ATF4+/2 animals versus N= 134 ATF4+/2/SOD1G86R
mice) (Table 1). As previously described, the generation rate of
ATF4 deficient animals was lower than expected with a
Mendelian rate calculation, which is possibly due to alterations
in amino acid metabolism [11]. Similar results were obtained
when the generation rate of ATF42/2 versus ATF42/2/
SOD1G86R was analyzed (Table 1). Taken together, these results
suggest that ATF4 deficiency reduces the probability of generating
experimental mutant SOD1 transgenic mice.
ATF4 deficiency delays disease onset and prolongs life
span in mutant SOD1 mice
Taking into account that we were able to generate viable
ATF42/2/SOD1G86R mice, we monitored disease progression
and survival of these animals. We measured body weight
progression and motor performance overtime starting from
early-asymptomatic disease stage. Based on a previous report
using perk+/2 mice [28], we expected that ATF4 deficiency would
exacerbate the progression of experimental ALS. Opposite to our
initial prediction, we observed a significant delay in disease onset
of ATF42/2/SOD1G86R mice assessed both by the reduction in
body weight (Figure 1A) and a decrease in motor performance
using the rotarod assay (Figure 1B). Analysis of body weight loss
indicated that, the average disease onset obtained was 130 days for
the ATF4+/+/SOD1G86R group compared with 183 days for
ATF42/2/SOD1G86R mice. Determination of disease onset using
the rotarod assay also showed a significant delay on disease
progression of ATF4 deficient mice, where the average disease
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onset was 147 days for the ATF4+/+/SOD1G86R group compared
with 209 days for ATF42/2/SOD1G86R mice. Although we
obtained eight ATF42/2/SOD1G86R mice, two of them did not
learn the rotarod task and were excluded from this analysis.
Mutant SOD1 transgenic mice showed a consistent survival
curve with low variability, with an average life span of
13765,4 days (Figure 1C). A robust and significant increase in
the life span of ATF42/2/SOD1G86R mice was observed (average
155627,1 days) compared with littermate control ATF4+/+/
SOD1G86R animals, with an extension in the life span of individual
animals ranging from 5 to 101 days longer than the average
ATF4+/+/SOD1G86R mice (Figure 1C; p=0.01). The duration of
the symptomatic phase of the disease, calculated from the time of
onset with the two parameters tested to the death of the animal,
was similar in ATF42/2/SOD1G86R and SOD1G86R mice on a
wild-type background (Figure 1D). Thus, ATF4 deficient animals
were more resistant to develop experimental ALS characterized by
a significant delay in disease onset and increased life span.
ATF4 deficiency leads to altered mutant SOD1
aggregation and histopathological features
We then analyzed ALS-related histological features in the spinal
cord of ATF42/2/SOD1G86R and littermate control mice. NeuN
staining was performed to visualize neuronal survival in the ventral
horn of the spinal cord, showing no significant differences in the
neuronal content of ATF4+/+/SOD1G86R and ATF42/2/
SOD1G86R mice at the end stage of the disease (Figure 2A). The
low reactivity to NeuN in SOD1 transgenic mice at this disease
stage is due to a massive loss of motoneurons in the model [39].
Similarly, ATF42/2/SOD1G86R mice presented similar content of
Olig2-positive cells, which identifies mature and precursor
oligodendrocytes, compared to SOD1G86R littermate control
animals (Figure 2A). In addition, no differences in GFAP staining
were observed in ATF42/2-SOD1G86R mice compared with the
ATF4+/+-SOD1G86R mice (astrocyte marker, Figure 2B). At basal
conditions, all these histological parameters were similar in both
ATF42/2 and ATF4+/+ mice as we recently reported [39]
(Figure S1).
We then monitored the levels of mutant SOD1 aggregation in
the frontal brain cortex and spinal cord tissue using total protein
extracts in the absence of a reducing agent to visualize mutant
SOD1 aggregates. Although variable levels of mutant SOD1
aggregation was observed at the late stage of the disease, an overall
tendency to increase SOD1 aggregation was detected in the spinal
cord (Figure 2C) and brain cortex (Figure 2D) of ATF42/2/
SOD1G86R mice, where only the latter showed significant
differences after statistical analysis. The levels of the monomeric
form of SOD1 were not affected by ATF4 deficiency.
Altered expression of ER chaperones and apoptosis-
related genes in mutant SOD1 mice deficient for ATF4
Protein disulfide isomerases (PDIs) are important UPR target
genes that constitute a large family of thiol-disulfide oxidoreduc-
tases responsible for the formation of disulfide bonds, playing
important roles in folding and protein quality control, in addition
to contribute to the redox status of the ER [40]. PDIs levels are
induced in ALS-derived tissue, which may have an impact on
SOD1 aggregation (reviewed in [41]). Besides, PDI has been also
shown to have a pro-apoptotic activity in models of neurodegen-
eration [42]. Based on this evidence, we monitored the levels of
major PDI-family members in the spinal cord of mutant SOD1
transgenic mice, including ERp57 (also known as Grp58), PDI,
and ERp72. Consistent with the role of ATF4 as an ER stress
transcription factor, the upregulation of ERp57 and PDI was
completed inhibited in ATF42/2/SOD1G86R animals when
compared to control SOD1G86R mice (Figure 3A, B). Similarly,
a partial reduction in BiP levels was detected in ATF42/2/
SOD1G86R spinal cord (Figure 3B). Unexpectedly, ATF4 defi-
ciency further enhanced the expression of ERp72 in SOD1G86R
mice, which may represent compensatory mechanism due to
ERp57 down regulation as previously suggested [43]. In contrast,
ERO1La levels (redox modulator of PDIs [40]) or XBP1 mRNA
splicing was not affected by ATF4 deficiency (Figure 3B and S2).
Since targeting ATF4 modulates autophagy in certain experimen-
tal systems, we monitored the rate of LC3 conversion. No
induction of total LC3 levels or the active LC3-II form was
observed in ATF42/2/ SOD1G86R mice (Figure 3A, B). As
positive control NSC34 cells treated with lysosomal inhibitors to
induce the accumulation of LC3-II (Figure S3).
ATF4 controls important pro-apoptotic genes including
CHOP/GADD153 and the BCL2 family member BIM. We
monitored the expression of CHOP and BIM in the spinal cord of
mutant SOD1 mice using Western blot analysis and real-time
PCR. Increased CHOP and BIM levels were detected in spinal
cord tissue derived from SOD1G86R mice, which were completely
prevented in ATF42/2 deficient animals at the protein (Figure 3C
and S4) and mRNA level (not shown). Overall, these data suggest
that ATF4 expression has two distinct consequences in ALS
pathogenesis: (i) it modulates mutant SOD1 aggregation, and (ii)
Figure 6. Working model. Accumulation of mutant SOD1 (SOD1mut) triggers ER stress engaging the UPR. Expression of ATF4 leads to the
expression of genes involved in apoptosis induction including CHOP and BIM, in addition to genes operating in redox control. On a feedback loop, ER
stress alters the redox status of the cell enhancing mutant SOD1 aggregation. ATF4 expression may attenuate SOD1 aggregation by controlling the
expression of genes involved in redox buffering.
doi:10.1371/journal.pone.0066672.g006
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drives the expression of several ER foldases and ER stress pro-
apoptotic factors.
Knocking down ATF4 in NSC34 motoneuron cells
enhances mutant SOD1 aggregation
To further investigate the contribution of ATF4 to mutant
SOD1 pathogenesis, we knocked down ATF4 in NSC34
motoneuron-like cells. NSC34 cells were stably transduced with
lentiviruses expressing a shRNA construct against atf4 mRNA
(shATF4). As control, a shRNA against the luciferase mRNA was
employed (shLuc). Knocking down ATF4 was highly efficient as
evidenced by a drastic reduction of ATF4, CHOP and PDI
expression in cells treated with the ER stress agent tunicamycin
(Tm) (Figure 4A). As expected, targeting ATF4 did not affect
XBP1 mRNA splicing (Figure 4A). Transient expression of
mutant SOD1 in shATF4 cells led to enhance aggregation of
mutant SOD1 by 50% as determined by Western blot analysis
(Figure 4B). Similarly, an increased number of cells containing
mutant SOD1-positive inclusions was observed when human
SOD1G85R-EGFP was transiently expressed in shATF4 cells
(Figure 4C).
ATF4 regulates the redox state of the cell impacting
mutant SOD1 aggregation
Based on previous reports linking ATF4 with the regulation of
genes related to redox metabolism at the ER [11], we measured
ROS content in shATF4 and control cells using dichlorodihy-
drofluorescein diacetate (DCF) staining, followed by FACS
analysis. A dramatic increase in DCF fluorescence was observed
in shATF4 cells at resting conditions (Figure 5A), which was
further enhanced after induction of ER stress with Tm treatment
(Figure 5A). To monitor the redox status of the ER, we expressed
the reporter construct HyPerERlum into shATF4 cells, which
locally monitors the generation of H2O2 inside the ER [33]. We
measured basal HyPerERlum fluorescence by live-cell imaging
microscopy and observed that knocking down ATF4 increased
H2O2 levels in the ER (Figure 5B). Upon ER stress induction
these differences were lost (Figure 5B) probably because of
saturation of the probe.
We also explored the possible contribution of oxidative stress
in the enhancement of mutant SOD1 aggregation found in
shATF4 cells. We treated NSC34 cells with the antioxidant
Trolox (a derivative of vitamin E), and then transfected cells with
expression vectors for SOD1G86R-EGFP. After 3 days of
expression, a slight, but significant, reduction in mutant SOD1
aggregation was observed when shATF4 cells where treated with
Trolox (Figure 5C). To modify the local production of H2O2 at
the ER we overexpressed ERO1La [33]. Co-expression of
ERO1La with SOD1G86R-EGFP in shATF4 significantly de-
creased mutant SOD1 aggregation and the accumulation of
SOD1 protein inclusion (Figure 5D). Taken together, these
results suggest that knocking down ATF4 in NSC34 cells alters
the ER redox environment, influencing mutant SOD1 aggrega-
tion. Finally, based on our results in the animal model of ALS
and in reports suggesting a protective role of ATF4 deficiency on
neuronal survival [21,22], we analyzed the susceptibility of
shATF4 motoneuron cells to ER stress-mediated cell death. As
shown in Figure 5E, knocking down ATF4 partially protected
cells against Tm toxicity. In contrast, shATF4 cells were sensitive
to the toxicity of etoposide (a DNA damage agent). Taken
together, these results suggest that ATF4 triggers global changes
in ER physiology that alters the susceptibility of cells to protein
folding stress.
Discussion
ALS is part of a large group of neurodegenerative diseases
classified as protein conformational disorders that are character-
ized by the presence of abnormal protein aggregates in the form of
inclusions or oligomers in affected neurons [44]. Although a small
fraction of ALS cases are linked to mutations in specific genes [1],
many studies have shown that the corresponding wild-type
proteins are also present in inclusions in human tissue derived
from sALS cases, including SOD1 [45], TDP-43 [46,47], and FUS
[48]. Consistent with this concept, the identification of mutations
in UBQLN2/Ubiquilin2 [49], p62/SQSTM1 [50], and PDI [51]
in ALS cases points out for a critical role of alterations in the
proteostasis network in the disease, where the disruption of
detoxification mechanisms emerges as a relevant factor for its
initiation and evolution. Since ER stress is an early molecular
event observed in ALS models, our current study places ATF4 as a
relevant modulator of ALS pathogenesis, revealing a new point for
future therapeutic intervention.
Our data, together with recent findings, suggests a complex
scenario where targeting distinct UPR components in ALS have
contrasting effects on disease progression. This notion is revealed
by the fact that deleting xbp1 attenuates ALS in mice [26], whereas
perk haplo-insufficiency accelerates the pathology. Similarly,
pharmacological induction of eIF2a phosphorylation [27], or
deletion of ASK1 [29] protects against ALS. Our results
demonstrate that the lack of ATF4 has two contrasting effects: it
protects against ALS progression in mutant SOD1 transgenic
animals, but it also results in a decreased probability to obtain
viable animals at birth. The possible cause underlying the
decreased generation of ATF42/2/SOD1G86R transgenic mice
is unknown. We speculate that the embryonic lethality of the
ATF42/2/SOD1G86R may be due in part to a combination of
slight developmental defects generated by ATF4 deficiency and
the presence of mutant SOD1 transgene. It remains to be
determined if targeting ATF4 in adult animals triggers similar
protective effects on ALS pathogenesis. It is also interesting to note
that, although the SOD1 transgenic line showed a consistent
survival curve with little dispersion, ATF4 deficiency generated a
large variability in terms of the extension of life span, suggesting
differential penetrance of the phenotype observed. Our results
suggest that ATF4 expression may alleviate neurotoxic effects of
mutant SOD1 occurring even during embryonic development of
the nervous system. Then, in adult animals sustained ATF4
expression due to chronic ER stress in ALS may have detrimental
effects through the induction of pro-apoptotic signals.
ATF4 has distinct effects in different models of neurodegener-
ative diseases. For example, we recently reported that targeting
ATF4 does not have any consequences on mutant huntingtin
aggregation in Huntingtons disease [52], whereas ATF4 deficiency
significantly reduces motor recovery after spinal cord injury [39].
Together with the current study, these reports illustrate the
complex function of ATF4 in cell physiology, reflecting the
divergent ways of how the UPR may impact specific diseases.
ATF4 is a stress-induced protein and a redox sensitive transcrip-
tion factor that is activated under oxidative stress conditions [11].
Our results agree with the view of ATF4 as a pro-death factor
possibly related to its major function as a stress integrator. This is
supported by the fact that many metabolic and danger signals
converge into eIF2a phosphorylation and ATF4 expression to
trigger survival programs or cell death if a critical level of damage
has been reached.
Although we detected a slight increase in aggregation of mutant
SOD1 in late symptomatic ATF4 deficient animals, these animals
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showed a delay in ALS progression. We speculate that the strong
repression of apoptosis-related genes in ATF4 deficient mice may
overcome the pathological events triggered by enhanced SOD1
aggregation observed in these animals. In addition, it may be
feasible that that low levels (non-lethal) of oxidative or ER stress in
ATF4 deficient neurons may triggers an adaptive response that
provides neuroprotection against mutant SOD1 toxicity as
suggested in other disease models [53]. Alternatively, it may be
also feasible that the generation of large SOD1 aggregates has a
neuroprotective role in our experimental system. In fact, it was
recently suggested that toxic mutant SOD1 species correspond to a
subpopulation of soluble oligomers, where the generation of large
SOD1 aggregates may actually provide neuroprotection through
the sequestration of toxic species [54]. This hypothesis has also
been proposed for Huntington’s disease [55] and other protein
misfolding disorders.
In summary, we postulate that the activation of ER stress by
mutant SOD1 induces a chronic response leading to the
expression of ATF4-dependent apoptosis genes, in addition to
influence the redox status of cell. The latter may feedback on
mutant SOD1 enhancing its aggregation (Figure 6). Our results
reinforce the concept that ER stress is a key event in ALS
pathogenesis, and identifies ATF4 as a novel target for the
development of future therapeutic interventions.
Supporting Information
Figure S1 Expression of neuronal, oligodendrocite and
glial markers in ATF4 deficient animals. (A) Immunoflu-
orescence analysis of NeuN (bar 200 mM), GFAP (bar 100 mM),
and Olig2 (bar mM) staining in spinal cord tissue derived from
ATF4+/+ and ATF42/2 mice.
(TIF)
Figure S2 XBP1 mRNA splicing in ATF4 deficient
animals. mRNA from motor cortex from ATF4+/+ non
transgenic animals (ATF4+/+ Non-Tg) and deficient for ATF4
(ATF42/2 Non-Tg) was prepared and then cDNA was obtained.
The splicing of XBP1 mRNA was measured by RT-PCR followed
by PstI digestion which only processes the unspliced form. XBP1
spliced (XBP1s) and unspliced (XBP1u) amplicons are shown.
Actin levels were monitored as a loading control. As a positive
control, NSC34 cells were treated or not with with 1 mg/ml
tunicamicyn (Tm) for 16 h.
(TIF)
Figure S3 LC3 detection in brain extracts. Expression
levels of autophagy marker LC3 was monitored in spinal cord
extracts derived from ATF4+/+, ATF42/2, ATF4+/+/SOD1G86R
and ATF42/2/SOD1G86R symptomatic mice using Western blot
analysis. The image was composed from representative bands
from the same gel and film. As a positive control for the detection
of the LC3-II form, NSC34 cells were treated with a cocktail of
lysosomal inhibitors including bafilomycin, pepstatin and E64D
(Lys. Inh).
(TIF)
Figure S4 CHOP and BIM protein expression in mutant
SOD1 transgenic mice. CHOP and BIM protein levels were
determined by Western Blot in spinal cord extracts derived from
ATF4+/+-Non Tg, ATF42/2-Non Tg, ATF4+/+/SOD1G86R and
ATF42/2/SOD1G86R symptomatic mice. HSP90 was used as
loading control. Quantification of these experiments is presented
in Figure 3C.
(TIF)
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